If you are interested in joining one of our clinical trials and want to find out if you qualify, please contact the Heart and Vascular Care Research Team 505-563-2716.
The purpose of this study is to assess the effect of sacubitril/valsartan (LCZ696) vs. valsartan on changes in NT-proBNP and outcomes, safety and tolerability in patients with HFpEF (left ventricular ejection fraction (LVEF) > 40%) who have been stabilized during hospitalization for acute decompensated heart failure and initiated in-hospital or within 30 days post discharge.
Principal Investigator: Lawrence A Nair, MD
NCT01524276
Updated: October 22, 2021
The purpose of the Registry is to provide continuing evaluation and periodic reporting of safety and effectiveness of Medtronic market-released products. The Registry data is intended to benefit and support interests of patients, hospitals, clinicians, regulatory bodies, payers, and industry by streamlining the clinical surveillance process and facilitating leading edge performance assessment via the least burdensome approach.
Learn more about the Product Surveillance Registry (PSR) trial